GLA (GAMMA LINOLENIC ACID) SAFFLOWER OIL
Juvenile Idiopathic Arthritis
FDA Office of Orphan Products DevelopmentSmall moleculeN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
14 Active assets in the Juvenile Idiopathic Arthritis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
METHOTREXATE National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 | CCC |
MODERNA COVID-19 VACCINE RNA National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 | CCC |
FILGRASTIM Paul Szabolcs | Phase 2 | CCC |
Cyclophosphamide Paul Szabolcs | Phase 2 | CCC |
Fludarabine Paul Szabolcs | Phase 2 | CCC |
View all 18 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →